Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma

J Am Acad Dermatol. 2002 Dec;47(6):956-61. doi: 10.1067/mjd.2002.124816.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Bexarotene
  • Biopsy, Needle
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Immunologic Factors / therapeutic use*
  • Lymphoma, T-Cell, Cutaneous / pathology*
  • Lymphoma, T-Cell, Cutaneous / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy*
  • Tetrahydronaphthalenes / therapeutic use*
  • Treatment Outcome
  • Ultraviolet Therapy / methods*

Substances

  • Immunologic Factors
  • Tetrahydronaphthalenes
  • Bexarotene